Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD

BMC Cancer

Table 3 Interaction between ICS use and lung infections

	HR (95 % CI)		p for ICS x pulmonary infection interaction
	No ICS	ICS	p for ICS x pulmonary infection interaction
Model 1
No lung infection	1	0.89 (0.68–1.16)	0.084
TB	1.42 (0.89–2.26)	2.48 (1.31–4.72)	0.084
Model 2
No lung infection	1	0.88 (0.67–1.15)	0.259
Pneumonia	0.93 (0.60–1.44)	1.17 (0.69–1.99)	0.259
Model 3
No lung infection	1	0.88 (0.67–1.16)	0.386
TB+pneumonia	1.65 (0.76–3.58)	2.38 (1.01–5.58)	0.386

Each model was adjusted by sex, age, medications, comorbidities, inpatient and outpatient visits for respiratory diseases, and urbanization

ISSN: 1471-2407